Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Multi-center, Randomized, Open-label Study of PCECV (Rabipur®) Comparing the Immunogenicity and Safety of Two Different Simulated Post Exposure Schedules (Zagreb 2-1-1 Versus Essen Regimen 1-1-1-1-1) in Healthy Indian Subjects

NCT01365494 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01365494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01365494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Multi-center, Randomized, Open-label Study of PCECV (Rabipur®) Comparing the Immunogenicity and Safety of Two Different Simulated Post Exposure Schedules (Zagreb 2-1-1 Versus Essen Regimen 1-1-1-1-1) in Healthy Indian Subjects
Lead sponsor
Novartis Vaccines
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2011
Completion date
November 30, 2011
Enrollment
250 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

rabies